Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 835-843

  Dhanasooraj, Dhananjayan ^a   Ajay Kumar, R ^a   Mundayoor, Sathish ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

CFP 10; Hepatitis B virus core particle; Mycobacterium tuberculosis; Self adjuvant; Vaccine delivery; VLP

Indexed keywords

CULTURE FILTRATE PROTEIN 10; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CFP 10 GENE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NANO SIZED HEPATITIS B VIRUS CORE VIRUS LIKE PARTICLES; NONHUMAN; PARTICLE SIZE; PLASMID; PROTEIN EXPRESSION; SPLEEN CELL; TRANSMISSION ELECTRON MICROSCOPY; TUBERCULOSIS; VIRUS LIKE AGENT;

CFP-10; HEPATITIS B VIRUS CORE PARTICLE; MYCOBACTERIUM TUBERCULOSIS; SELF-ADJUVANT; VACCINE DELIVERY; VLP;

ANIMALS; BACTERIAL PROTEINS; CELL PROLIFERATION; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; HEPATITIS B CORE ANTIGENS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; SPLEEN; TUBERCULOSIS VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84874822639     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40238     Document Type: Article

References (58)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science. 2010;328(5980):856-861.
2. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698-702.
3. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22(6):1154-1158.
4. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med. 1996;335(26):1956-1961.
5. Skwarczynski M, Toth I. Peptide-based subunit nanovaccines. Curr Drug Deliv. 2011;8(3):282-289.
6. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol. 2000;30(12):3689-3698.
7. Andersen P, Askgaard D, Ljungqvist L, Bentzon MW, Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun. 1991;59(4):1558-1563.
8. Agger EM, Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine. 2001;19(17-19):2298-2302.
9. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun. 2001;69(5):2773-2778.
10. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun. 1994;62(6):2536-2544.
11. Horwitz MA, Lee BW, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1995;92(5): 1530-1534.
12. Zhang H, Wen K, Shen J, et al. Characterization of immune responses following intranasal immunization with the Mycobacterium bovis CFP-10 protein expressed by attenuated Salmonella typhimurium. Scand J Immunol. 2010;72(4):277-283.
13. Christy AJ, Dharman K, Dhandapaani G, et al. Epitope based recombinant BCG vaccine elicits specific Th1 polarized immune responses in BALB/c mice. Vaccine. 2012;30(7):1364-1370.
14. Arend SM, Geluk A, van Meijgaarden KE, et al. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun. 2000;68(6): 3314-3321.
15. Qiao D, Li L, Guo J, et al. Mycobacterium tuberculosis culture filtrate protein 10-specific effector/memory CD4(+) and CD8(+) T cells in tubercular pleural fluid, with biased usage of T cell receptor Vbeta chains. Infect Immun. 2011;79(8):3358-3365.
16. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752-3762.
17. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009;462(7272):449-460.
18. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010; 13(1):106-112.
19. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods. 2006;40(1):60-65.
20. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010; 10(11):787-796.
21. Fifis T, Gamvrellis A, Crimeen-Irwin B, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173(5):3148-3154.
22. Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008;181(11):7948-7957.
23. Millington KA, Fortune SM, Low J, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A. 2011;108(14):5730-5735.
24. Yu F, Wang J, Dou J, et al. Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine. 2012;8(8):1337-1344.
25. Griffiths G, Nystrom B, Sable SB, Khuller GK. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol. 2010;8(11):827-834.
26. Bivas-Benita M, Lin MY, Bal SM, et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine. 2009;27(30):4010-4017.
27. Wizemann H, von Brunn A. Purification of E. coli-expressed HIS-tagged hepatitis B core antigen by Ni2+-chelate affinity chromatography. J Virol Methods. 1999;77(2):189-197.
28. Vogel M, Diez M, Eisfeld J, Nassal M. In vitro assembly of mosaic hepatitis B virus capsid-like particles (CLPs): rescue into CLPs of assembly-deficient core protein fusions and FRET-suited CLPs. FEBS Lett. 2005;579(23):5211-5216.
29. Hubbard RD, Flory CM, Collins FM. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol. 1992;87(1): 94-98.
30. Wu Y, Woodworth JS, Shin DS, Morris S, Behar SM. Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infect Immun. 2008;76(5):2249-2255.
31. Stukova MA, Sereinig S, Zabolotnyh NV, et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb). 2006;86(3-4):236-246.
32. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis. 1993;167(6):1481-1497.
33. Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun. 2003;71(8):4225-4228.
34. Williams A, Reljic R, Naylor I, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 2004;111(3):328-333.
35. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol. 1990;8:303-333.
36. Natsuume-Sakai S, Motonishi K, Migita S. Quantitative estimations of five classes of immunoglobulin in inbred mouse strains. Immunology. 1977;32(6):861-866.
37. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993;178(6):2249-2254.
38. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4856):1169-1176.
39. Zhang M, Lin Y, Iyer DV, Gong J, Abrams JS, Barnes PF. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun. 1995;63(8):3231-3234.
40. Young S, O'Donnell M, Lockhart E, et al. Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2-and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol. 2002;80(3):209-215.
41. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A. 1992;89(24):12013-12017.
42. Chen CY, Huang D, Wang RC, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 2009;5(4): e1000392.
43. Bogdan C, Moll H, Solbach W, Rollinghoff M. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol. 1990;20(5):1131-1135.
44. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol. 2001;166(11):6728-6734.
45. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998;32(3):155-172.
46. Sun HX, Qin F, Ye YP. Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng. Vaccine. 2005;23(48-49):5533-5542.
47. McMurray DN. Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis. Scand J Infect Dis. 2001;33(3): 175-178.
48. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine. 2006;24 Suppl 2:S2-26-29.
49. Yang X, Bao L, Deng Y. A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity. Acta Biochim Biophys Sin (Shanghai). 2011;43(7):511-518.
50. Soltysik S, Wu JY, Recchia J, et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine. 1995;13(15):1403-1410.
51. Wangoo A, Sparer T, Brown IN, et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol. 2001;166(5):3432-3439.
52. Yin Y, Li H, Wu S, et al. Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses. Vaccine. 2011;29(34):5645-5651.
53. Pumpens P, Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett. 1999;442(1):1-6.
54. Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol. 2005;79(2):717-724.
55. Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci U S A. 1999;96(5):1915-1920.
56. Newman M, Suk FM, Cajimat M, Chua PK, Shih C. Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. J Virol. 2003;77(24):12950-12960.
57. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol. 2002;32(3):818-825.
58. Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002;20(25-26):3104-3112.